Status:
WITHDRAWN
Relevance Evaluation of [68Ga]Ga-PentixaFor for Initial Staging and Detection of Minimal Residual Disease in Multiple Myeloma Patients.
Lead Sponsor:
Nantes University Hospital
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The aim of our study is to confirm the relevance of PET using \[68Ga\]Ga-PentixaFor ligand, in comparison with FDG, for initial staging and detection of minimal residual disease in multiple myeloma pa...
Eligibility Criteria
Inclusion
- Inclusion criteria are identical to inclusion criteria in MIDAS study (EudraCT Number: 2020-005216-21, ClinicalTrials.gov Identifier: NCT04934475) .
Exclusion
- Non inclusion criteria are identical to non inclusion criteria in MIDAS study (EudraCT Number: 2020-005216-21, ClinicalTrials.gov Identifier: NCT04934475) added with:
- eGFR \< 50 ml/min by MDRD or CKDEPI.
- Previous or concurrent second malignancy except for adequately treated basal cell carcinoma of the skin, curatively treated in situ carcinoma of the cervix, curatively treated solid cancer, with no evidence of disease for at least 2 years.
- Patient with uncontrolled insulin-dependent or non-insulin-dependent diabetes mellitus.
Key Trial Info
Start Date :
March 14 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 4 2023
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT05321862
Start Date
March 14 2023
End Date
May 4 2023
Last Update
November 15 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Nantes
Nantes, France